- Home
- XXII vs SXTP Comparison
XXII vs SXTP Comparison
Compare XXII & SXTP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | XXII | SXTP |
|---|---|---|
| Founded | 1998 | 2010 |
| Country | United States | United States |
| Employees | N/A | 3 |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.3M | 3.9M |
| IPO Year | 2011 | N/A |
Fundamental Metrics
Financial Performance| Metric | XXII | SXTP |
|---|---|---|
| Price | $0.54 | $1.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $14.10 |
| AVG Volume (30 Days) | ★ 1.3M | 54.8K |
| Earning Date | 05-12-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.96 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $25,832,530.00 | N/A |
| Revenue This Year | $370.28 | $33.92 |
| Revenue Next Year | N/A | $51.35 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.51 | $0.34 |
| 52 Week High | $11.37 | $8.62 |
Technical Indicators
Market Signals| Indicator | XXII | SXTP |
|---|---|---|
| Relative Strength Index (RSI) | 22.08 | 44.87 |
| Support Level | $0.51 | $1.30 |
| Resistance Level | $1.15 | $1.52 |
| Average True Range (ATR) | 0.08 | 0.09 |
| MACD | 0.06 | 0.02 |
| Stochastic Oscillator | 12.14 | 54.51 |
Price Performance
Historical ComparisonAbout XXII 22nd Century Group Inc.
22nd Century Group Inc is a United States-based biotechnology company focused on utilizing alkaloid plant technologies to improve health and wellness with reduced nicotine tobacco, and hemp/cannabis. It has one operating segment; The tobacco segment is engaged in commercializing its proprietary VLNC tobacco plants and cigarette products, which contain nicotine than conventional tobacco and cigarettes, and research cigarettes sold under the brand name SPECTRUM. It derives a majority of its revenue from the tobacco segment.
About SXTP 60 Degrees Pharmaceuticals Inc.
60 Degrees Pharmaceuticals Inc operates as a specialty pharmaceutical company with the goal of using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. Currently, company's pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company's future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.